WO1990012571A1 - Compositions and methods for administering vitamin c - Google Patents
Compositions and methods for administering vitamin c Download PDFInfo
- Publication number
- WO1990012571A1 WO1990012571A1 PCT/US1989/001642 US8901642W WO9012571A1 WO 1990012571 A1 WO1990012571 A1 WO 1990012571A1 US 8901642 W US8901642 W US 8901642W WO 9012571 A1 WO9012571 A1 WO 9012571A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- vitamin
- compound
- ascorbate
- activity
- acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
Definitions
- This invention relates to an improved form of Vitamin C.
- the invention concerns improved methods for establishing Vitamin C levels in the human body.
- the invention pertains to methods for improving the human body tolerance to Vitamin C.
- the invention relates to a
- Vitamin C derivative composition which is more effectively absorbed and retained in the human body.
- Vitamin C which is required by the human body for the various metabolic reactions discussed above must be ingested with the human diet.
- the human body does not have the ability to store Vitamin C — if unmetabolized, it is excreted.
- Low levels of Vitamin C and its derivatives in the human body produce a variety of undesirable physiological responses and extremely low levels produce extreme responses which may result in death, e.q., from scurvy. Wholly apart from these
- Vitamin C is important is some therapeutic modalities to establish and maintain above-normal Vitamin C levels in the body. These above- normal concentrations are difficult to establish and maintain because the human body exhibits only a finite tolerance for Vitamin C, with resultant diarrhea and other side reactions, such as gastric irritation and inflammation if these tolerances are exceeded.
- compositions and methods for improving the establishment and maintenance of high levels of Vitamin C (including its derivatives) in the human body comprises a compound having Vitamin C activity and at least one compound selected from the class consisting of the aldono-lactones and edible salts of L- threonic, L-xylonic and L-lyxonic acids.
- a method which I have discovered for establishing Vitamin C levels in the human body includes the step of orally administering this composition to a subject.
- Another method of the invention comprises the step of converting L-ascorbic acid to this composition and orally administering this composition to the subject.
- Vitamin C L-ascorbic acid
- derivatives include, for example, oxidation products such as dehydroascorbic acid and edible salts of ascorbic acid such as, illustratively, calcium, sodium, magnesium, potassium and zinc ascorbates.
- the metabolites of ascorbic acid and its derivatives include the aldo-lactones and edible salts of aldonic acids.
- the compositions of the present invention are characterized by the presence of at least one or more of these metabolites corresponding to three specific aldonic acids: L-threonic acid, L-xylonic acid and L-lyxonic acid.
- compositions of the invention are both a convenient way of identifying such compositions and is also necessary to achieve the desired result, improvement in Vitamin C absorption and/or retention.
- compositions of the invention which, as indicated above, has "Vitamin C activity" can be L-ascorbic acid or any of its derivatives which have the ability to provide the ascorbic/ascorbate moiety in physiologic processes, e.g., dehydroascorbic acid, calcium ascorbate which are most commonly employed in Vitamin C food supplements, as well as a wide variety of other edible (non-toxic) salts such as potassium, sodium. magnesium and zinc ascorbate. In general, any such compound which exhibits C-vitaminic activity will suffice and this can be conveniently determined by the well-known standard "iodine test.”
- a suitable method for preparing the compositions of the invention comprises reacting L-ascorbic acid with a non-toxic metal compound, e.g.-, calcium carbonate, sodium bicarbonate, under oxidizing conditions at an elevated temperature, e.g., 40°C-98 ⁇ C, to convert a substantial proportion of the ascorbic acid to its corresponding salt, e.g., calcium or sodium ascorbate, and drying the reaction mixture to produce a solid product of essentially neutral pH (e.g., 6.0-7.2).
- a slight stoichiometric excess of the metal salt reactant is provided.
- the resultant product has an iodine ascorbate activity in the range 100-400 mg./500 mg. sample with the higher activity preferred for practical reasons. Longer heating at oxidizing conditions produces lower iodine ascorbate activity.
- compositions of the invention appear useful in administering Vitamin C to patients who have low ascorbic acid tolerance.
- patients who have a tendency to form kidney stones are particularly susceptible to difficulties when ingesting ascorbic acid and its common derivatives, calcium ascorbate, which cause elevated urine oxalate levels.
- the compositions of the present invention can be administered without increasing the oxalate level in the urine to the levels encountered when the prior art compositions are ingested. Therefore, the present compositions and methods are especially suitable as a means of establishing and maintaining ascorbate body levels in such kidney stone-prone subjects.
- the following examples are presented for purposes of illustrating the practice of the invention and are not intended as limitations on the scope thereof.
- Ascorbic acid-U.S.P. 110.23 lbs. was added in one portion to the hot water.
- the resulting slurry was mechanically stirred and heated with steam (pressure 15 p.s.i.) until a temperature of 70°C was achieved.
- Assays were performed immediately on 5.00 g. samples dissolved in 500 ml. distilled water. The material collected during the drying process showed 400 mg. ascorbate activity per 500 mg. by the standard iodine titration technique. The same aqueous solution showed pH 7.0.
- Example 1 The following example describes clinical tests comparing the product of Example 1 (test) with L-ascorbic acid and citric acid (placebo) , measuring intracellular ascorbate levels, urinary ascorbate output and urinary oxalate excretion at various times after ingestion of standard doses of the test, L-ascorbic acid and placebo.
- Citric Acid Group 3000 MG of citric acid per day.
- Oxalate is oxidized to hydrogen peroxide and carbon dioxide by oxalate oxidase.
- the hydrogen peroxide reacts with 3-methyl-2-benzothiozolinone hydrazone (MBTH) and 3 (dimethylamino) benzoic acid (DMAB) in the presence of peroxidase to yield an indamine dye with a maximum absorbance at 590 NM.
- MBTH 3-methyl-2-benzothiozolinone hydrazone
- DMAB dimethylamino benzoic acid
- test groups had higher serum ascorbate level as compared to both the citrate group and the L-ascorbic group.
- WBC Ascorbate Level
- test group had the smallest percentage decrease.
- test group had the smallest percentage decrease.
- Four and 24-hour measurement plus the 7th day level showed that the test group was able to maintain the highest white blood cell ascorbate level.
- test groups had less ascorbate output than L-ascorbic.
- Test groups have less ascorbate output than the citrate and the L-ascorbic groups.
- Oxalate output is greatly decreased in the test group as compared to the ascorbic group. This means that while taking test product as a supplement, a person has less chance of forming oxalate-containing kidney calculi than a person taking L-ascorbic.
- Prolonged supplementation with test product leads to less excretion of urinary oxalate than supplementation with L-ascorbic.
- the temperature is raised to 80 ⁇ C. Further additions of calcium carbonate are begun, the temperature being maintained in the range 60 ⁇ C to about 70 ⁇ C.
- the total quantity of calcium carbonate added is 125g (1.25 moles).
- the reaction mixture is transferred to a shallow container maintained at a temperature of between 60"C and 80 ⁇ C, for a period of from 12 to 36 hours, during which time the pH of the mixture rises to a pH range of 6.0- 7.0. At this point, the excess water is removed under vacuum.
- Ascorbic acid, calcium ascorbate and dehydroascorbic acid were separated from the product by chromatography and the residue was subjected to nuclear magnetic resonance spectroscopy. Likely possibilities for the structures of the components detected by spectroscopy were formulated and these authentic compounds were then synthesized. After nmr spectra of these authentic compounds were obtained, they were compared to the nmr spectra of the test specimens. A match of the spectra was used to identify the components of the test specimens.
- the techniques employed were 1 H and 13 C nmr.
- the aldonic acid salts identified are the calcium salts of L- threonic acid, L-xylonic acid and L-lyxonic acid.
- Example 1 The procedures of Example 1 are repeated except that the reactant added to the ascorbic acid is changed to yield correspondingly different edible salts of ascorbic acid.
- Reactant Salt sodium bicarbonate sodium ascorbate magnesium carbonate magnesium ascorbate potassium bicarbonate potassium ascorbate zinc oxide zinc ascorbate
- the aldonic acid derivatives include derivatives of the indicated acid in the following approximate proportions:
- Example 2 The procedure of Example 1 is repeated except that no metal compound reactant (e.g., calcium carbonate) is added.
- the ascorbic acid is, however, subjected to the same oxidizing, heating, drying steps.
- the product consists of anhydrous ascorbic acid product, DHA water and aldo-lactone derivatives of threonic, xylonic and lyxonic acids. This product yields similar physiological results to those described in Example 8.
- Example 2 The procedures of Example 2 are repeated except that the test product is synthesized by mixing reagent grade calcium ascorbate with
- Test A Threonic Acid (calcium salt) Test B - Xylonic Acid (calcium salt) Test C - Lyxonic Acid (calcium salt)
- Example 2 The tests of Example 2 are repeated using these test compounds and using pure calcium ascorbate as an additional control.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
A composition useful for administering Vitamin C to a subject comprises a compound having Vitamin C activity and at least one compound selected from the class consisting of the aldono-lactones and edible salts of L-threonic, L-xylonic and L-lyxonic acids. Methods are provided for improving the body absorption rate of a Vitamin C compound comprising the step of incorporating therein a minor effective amount of a metabolite of the compound. Further methods are disclosed for improving the absorption rate of Vitamin C to a composition including a Vitamin C compound and at least one compound selected from the class consisting of the aldono-lactones and edible salts of L-threonic, L-xylonic and L-lyxonic acids, and administering this composition to the subject.
Description
COMPOSITIONS AND METHODS FOR ADMINISTERING VITAMIN C
This invention relates to an improved form of Vitamin C.
In another respect, the invention concerns improved methods for establishing Vitamin C levels in the human body.
In yet another respect, the invention pertains to methods for improving the human body tolerance to Vitamin C.
In still another respect, the invention relates to a
Vitamin C derivative composition which is more effectively absorbed and retained in the human body.
Prior workers have identified over 300 separate metabolic mechanisms in which Vitamin C is involved in physiologic reactions. These mechanisms range from the antiscorbutic effect first observed by Dr. Robert Lind in 1740 to more recently discovered anti-oxidant free- radical scavenging reactions, the co-reaction with enzymes in the formation of collagen, energy metabolism accentuation in the polynuclearleucosites and facilitation of iron absorption.
The clinical effects of such metabolic reactions have been widely recognized and reported. For example, the free-radical scavenging effect is believed to enable the body to convert carcinogens to non-toxic derivatives which are eliminated in the urine and, consequently, to ameliorate the effects of smoking and exposure of the body to other environmental pollutants. Animal studies have demonstrated that body enzymes convert ascorbates to oxidation products which have demonstrated tumor growth inhibition.
Conseguently, there is little scientific doubt that the establishment and maintenance of effective levels of Vitamin C and its derivatives in the human body yield important health advantages. The presence of Vitamin C in substantial concentration has been observed in the adrenals, ovaries, brain, pituitaries, liver, spleen, blood cells, blood serum, and extracellular lung liquids.
Most animals have a liver enzyme which enables them to actually manufacture Vitamin C in situ by conversion of blood sugar into ascorbic acid. However, humans do not have this enzyme. As a consequence, the Vitamin C which is required by the human body for the various metabolic reactions discussed above must be ingested with the human diet. Furthermore, the human body does not have the ability to store Vitamin C — if unmetabolized, it is excreted. Low levels of Vitamin C and its derivatives in the human body produce a variety of undesirable physiological responses and extremely low levels produce extreme responses which may result in death, e.q., from scurvy. Wholly apart from these
"normal" requirements of Vitamin C, it is important is some therapeutic modalities to establish and maintain above-normal Vitamin C levels in the body. These above- normal concentrations are difficult to establish and maintain because the human body exhibits only a finite tolerance for Vitamin C, with resultant diarrhea and other side reactions, such as gastric irritation and inflammation if these tolerances are exceeded.
I have now discovered compositions and methods for improving the establishment and maintenance of high levels of Vitamin C (including its derivatives) in the human body. Briefly, the composition which I have discovered comprises a compound having Vitamin C activity and at least one compound selected from the class consisting of the aldono-lactones and edible salts of L- threonic, L-xylonic and L-lyxonic acids.
A method which I have discovered for establishing Vitamin C levels in the human body includes the step of orally administering this composition to a subject.
Another method of the invention comprises the step of converting L-ascorbic acid to this composition and orally administering this composition to the subject.
As used herein, the term "compound having Vitamin C activity" means Vitamin C (L-ascorbic acid) and any derivative thereof which exhibits ascorbitic activity as determined by the standard iodine titration test. Such derivatives include, for example, oxidation products such as dehydroascorbic acid and edible salts of ascorbic acid such as, illustratively, calcium, sodium, magnesium, potassium and zinc ascorbates.
The metabolites of ascorbic acid and its derivatives include the aldo-lactones and edible salts of aldonic acids. As will appear, the compositions of the present invention are characterized by the presence of at least one or more of these metabolites corresponding to three specific aldonic acids: L-threonic acid, L-xylonic acid and L-lyxonic acid.
The presence of one or more of these metabolites in the compositions of the invention is both a convenient way of identifying such compositions and is also necessary to achieve the desired result, improvement in Vitamin C absorption and/or retention.
The component of the compositions of the invention which, as indicated above, has "Vitamin C activity" can be L-ascorbic acid or any of its derivatives which have the ability to provide the ascorbic/ascorbate moiety in physiologic processes, e.g., dehydroascorbic acid, calcium ascorbate which are most commonly employed in Vitamin C food supplements, as well as a wide variety of other edible (non-toxic) salts such as potassium, sodium.
magnesium and zinc ascorbate. In general, any such compound which exhibits C-vitaminic activity will suffice and this can be conveniently determined by the well-known standard "iodine test."
A suitable method for preparing the compositions of the invention comprises reacting L-ascorbic acid with a non-toxic metal compound, e.g.-, calcium carbonate, sodium bicarbonate, under oxidizing conditions at an elevated temperature, e.g., 40°C-98βC, to convert a substantial proportion of the ascorbic acid to its corresponding salt, e.g., calcium or sodium ascorbate, and drying the reaction mixture to produce a solid product of essentially neutral pH (e.g., 6.0-7.2). Preferably, a slight stoichiometric excess of the metal salt reactant is provided. The resultant product has an iodine ascorbate activity in the range 100-400 mg./500 mg. sample with the higher activity preferred for practical reasons. Longer heating at oxidizing conditions produces lower iodine ascorbate activity.
The compositions of the invention appear useful in administering Vitamin C to patients who have low ascorbic acid tolerance. In particular, patients who have a tendency to form kidney stones are particularly susceptible to difficulties when ingesting ascorbic acid and its common derivatives, calcium ascorbate, which cause elevated urine oxalate levels. It has now, however, been discovered that the compositions of the present invention can be administered without increasing the oxalate level in the urine to the levels encountered when the prior art compositions are ingested. Therefore, the present compositions and methods are especially suitable as a means of establishing and maintaining ascorbate body levels in such kidney stone-prone subjects.
The following examples are presented for purposes of illustrating the practice of the invention and are not intended as limitations on the scope thereof.
EXAMPLE 1
To an 80 gallon, steam-heated stainless steel reaction vessel was added 60*ibs. of hot (44°C) water.
Ascorbic acid-U.S.P., 110.23 lbs., was added in one portion to the hot water. The resulting slurry was mechanically stirred and heated with steam (pressure 15 p.s.i.) until a temperature of 70°C was achieved.
To the aqueous slurry of ascorbic acid was added 23 lbs. of calcium carbonate. The incremental addition of the carbonate required 3-4 minutes. The reaction mixture appeared gray in color and much foaming due to the evolution of C02 was evident.
After eight minutes of stirring, most of the foaming had subsided and the reaction mixture appeared red-brown in color. The reaction temperature was 80°C.
Stirring and heating were continued for 15 minutes until the temperature of the reaction mixture reached 98"C where it was maintained for an additional 20 minutes, during minutes, during which an additional 8.25 lbs. of calcium carbonate was added, with stirring. The reaction mixture was then pumped to a double-drum steam- heated dryer (surface temperature 250°F) . The pumping- drying step required 35 minutes. The dried product was light-tan color and the yield was approximately 120 pounds of product.
Assays were performed immediately on 5.00 g. samples dissolved in 500 ml. distilled water.
The material collected during the drying process showed 400 mg. ascorbate activity per 500 mg. by the standard iodine titration technique. The same aqueous solution showed pH 7.0.
EXAMPLE 2
The following example describes clinical tests comparing the product of Example 1 (test) with L-ascorbic acid and citric acid (placebo) , measuring intracellular ascorbate levels, urinary ascorbate output and urinary oxalate excretion at various times after ingestion of standard doses of the test, L-ascorbic acid and placebo.
Summary of the Protocol
Twelve men, ages 27 to 45, were studied.
All were instructed that they should be on a low Vitamin C diet for one week prior to the study. (No citrus products and no large amounts of green leafy vegetables. )
Following overnight fast, blood and 24-hour urine samples were taken. While blood cell and 24-hour urinary ascorbate and oxalate levels were determined and correlated with serum ascorbate levels.
The 12 men "were divided into three groups, and were given the following supplements:
(a) Test Group: 4000 MG* per day of the product Ex. 1.
(b) Ascorbate Group: 3000 MG of L- ascorbic per day.
4000 mg is equivalent in ascorbate activity (iodine test) to 3000 mg L-ascorbic acid.
(c) Citric Acid Group: 3000 MG of citric acid per day.
All 12 continued on the low Vitamin C diet. Blood samples were taken at 0, 4, 8 and 24 hours after morning ingestion of the designated supplements. Urinary 24-hour ascorbate and oxalate levels were determined.
After a wash-out period (varying from two days to several days, due to job situation of the participants), the groups were switched to another supplement, as follows:
(a) Test group to citrate group
(b) Citrate group to ascorbate group
(c) Ascorbate group to test group
Supplements were taken at the same level (4000 MG of EX. l product, 3000 MG of L-ascorbic and 3000 MG of citric acid) by all three groups. Blood samples were again drawn at 0, 4, 8 and 24 hours from time of ingestion. A 24-hour urine was also collected by all 12 participants at the end of the period. Again, all specimens were analyzed for their respective concentration of ascorbate and oxalate level.
Analytical Procedures
The analytical procedures utilized are described in:
Clinical Chemistry, Principles and Techniques. edited by Richard J.
Henry, Donald D. Cannon and James W. Windelman, Harper and Row, 1974, p. 1393-1398.
Standard Methods of Clinical Chemistry, J. S. Roe, edited by
Seligson D. New York, Academic Press, 1961, Vol. 3, p. 35.
In the quantitation of 24-hour urine oxalate, an aliquot of urine is shaken with an adsorbent which selectively binds the oxalate. The extracted urine is discarded and the oxalate is eluted from the adsorbent with dilute alkali.
Oxalate is oxidized to hydrogen peroxide and carbon dioxide by oxalate oxidase. The hydrogen peroxide reacts with 3-methyl-2-benzothiozolinone hydrazone (MBTH) and 3 (dimethylamino) benzoic acid (DMAB) in the presence of peroxidase to yield an indamine dye with a maximum absorbance at 590 NM.
The urine oxalate test is further described in the following references:
Hodgekinson, A, : Oxalic Acid in Violocrv and Medicine. Academic Press, New York, 1977.
Robertson, W.D. ; Rutherford, A.: Aspects of the Analysis of Oxalate in
Urine. Scan J. Uro Nephrol, Suppl. 53, p. 85, 1979.
Lamden, M. P.; Chrystowski, G. A.: Urinary Oxalate Excretion by Main Following Ascorbine Acid Ingestion.
Prog. Soc. Exp. Biol. Med. 85:190, 1954.
Costello, J.: The Effect of Ascorbic Acid on Oxalate Metabolism in Human Biochemistry and Clinical Pathology. edited by G. A. Rose, W. G. Robertson and R. W. E. Watts. Proceedings of
an International Meeting in London, 1971, pp. 270-273.
The results of this clinical study are set forth below:
Table 1
Percent Change* in Group
Serum Ascorbate Level Citrate L-ascorbic Test
4th Hour 10 180.3 264.8
8th Hour 19.6 91.6 144.2
24th Hour 5.9 24.6 56.2
7th day 45.3 102.5
White Blood Cell (WBC Ascorbate Level
4th Hour -40. .5 34.1 38
8th Hour -21. .2 -21.9 -6.80
24th Hour -6. .3 -5.3 18.2
7th Day 27.6 30.5 24th Hour Urine Ascorbate
% Change 27, .7 2760.6 480.3
MG/24 Hour 43, .65 314.5 252 7th Day Urine Ascorbate
%Change 4583 617
MG/24 Hour 459 321 24th Hour Urine Oxalate
% Change • 7 162 35.9
MG/24 Hr. 25.9 63.8 41.6 ♦increase unless otherwise indicated.
The conclusions which were drawn from this study are:
Serum Ascorbate Level:
At 4, 8 and 24 hours and 7 days later, test groups had higher serum ascorbate level as compared to both the citrate group and the L-ascorbic group. WBC Ascorbate Level:
Although all 8th hour WBC ascorbate groups showed an average decrease, test group had the smallest percentage decrease. Four and 24-hour measurement plus the 7th day level showed that the test group was able to maintain the highest white blood cell ascorbate level.
24-Hour WBC Ascorbate:
24-hour post various loadings of: citrate, L- ascorbic and test produce —
Both the citrate group and L-ascorbic group showed a decrease in WBC ascorbate levels. Test group maintained a much higher level compared to baseline.
7 Days Post Loading of L-Ascorbic and Test: Average percentages change in WBC Ascorbate is still higher in the Test Group than in the L-ascorbic group.
24-Hour Urine Ascorbate Output:
Both in average percentage change and in absolute total mean values, the test groups had less ascorbate output than L-ascorbic.
7 Days - 24 Hour Urinary Ascorbate Output:
Test groups have less ascorbate output than the citrate and the L-ascorbic groups.
24-Hour Urinary Oxalate Output: Oxalate output is greatly decreased in the test group as compared to the ascorbic group. This means that while taking test product as a supplement, a person has
less chance of forming oxalate-containing kidney calculi than a person taking L-ascorbic.
7 Day 24 Hour Oxalate Output:
Prolonged supplementation with test product leads to less excretion of urinary oxalate than supplementation with L-ascorbic.
EXAMPLE 3
To a 2-litre reaction vessel equipped with an agitator and a thermometer is added 300ml distilled water and 440g (2.5 moles) L-ascorbic acid. To this stirred slurry, finely divided calcium carbonate is added incrementally at a rate such as to produce a constant evolution of carbon dioxide (reaction byproduct) , the reaction temperature being maintained at about 20"C. The addition of calcium carbonate is suspended after about
25g to 37.5g have been added (representing from about 20% to 30% of that required for complete reaction with the L-ascorbic acid charge) .
At this point, the temperature is raised to 80βC. Further additions of calcium carbonate are begun, the temperature being maintained in the range 60βC to about 70βC. The total quantity of calcium carbonate added is 125g (1.25 moles).
The reaction mixture is transferred to a shallow container maintained at a temperature of between 60"C and 80βC, for a period of from 12 to 36 hours, during which time the pH of the mixture rises to a pH range of 6.0- 7.0. At this point, the excess water is removed under vacuum.
The dry products are light tan in color and readily soluble in water, except for unreacted calcium carbonate, to produce neutral solutions.
EXAMPLE 4
Clinical studies using the product of Example 3 yield similar results to those set forth in Example 2.
EXAMPLE 5
The products of Examples—1 and 3 are subjected to qualitative analysis, as follows:
Ascorbic acid, calcium ascorbate and dehydroascorbic acid were separated from the product by chromatography and the residue was subjected to nuclear magnetic resonance spectroscopy. Likely possibilities for the structures of the components detected by spectroscopy were formulated and these authentic compounds were then synthesized. After nmr spectra of these authentic compounds were obtained, they were compared to the nmr spectra of the test specimens. A match of the spectra was used to identify the components of the test specimens.
The techniques employed were 1H and 13C nmr. The aldonic acid salts identified are the calcium salts of L- threonic acid, L-xylonic acid and L-lyxonic acid.
EXAMPLE 6
The procedures of Example 1 are repeated except that the reactant added to the ascorbic acid is changed to yield correspondingly different edible salts of ascorbic acid. Reactant Salt sodium bicarbonate sodium ascorbate magnesium carbonate magnesium ascorbate potassium bicarbonate potassium ascorbate zinc oxide zinc ascorbate
These products produce similar physiological results to those described in Example 2 and contain the aldonic acid salts corresponding to those" identified in Example 5.
EXAMPLE 7
Quantitative analysis of the products of Examples 1, 4, and 6 is performed. The products have the indicated compositions:
Wt. %
Anhydrous metal ascorbate 80-82
Unreacted metal reagent 6-7 Dehydroascorbic Acid 3-8
Moisture 1.5-3
Aldonic Acid Derivatives 5-6
The aldonic acid derivatives include derivatives of the indicated acid in the following approximate proportions:
Acid (Derivative) Parts by Weight
Threonic 8
Xylonic 3
Lyxonic 1
There are indications that one or more of these aldonic acids may be partially linked.
EXAMPLE 8
Animal feeding studies of the product of Example 1 provide similar results to the human studies of Example 2.
EXAMPLE 9
The procedure of Example 1 is repeated except that no metal compound reactant (e.g., calcium carbonate) is
added. The ascorbic acid is, however, subjected to the same oxidizing, heating, drying steps. The product consists of anhydrous ascorbic acid product, DHA water and aldo-lactone derivatives of threonic, xylonic and lyxonic acids. This product yields similar physiological results to those described in Example 8.
EXAMPBE 10
The procedures of Example 2 are repeated except that the test product is synthesized by mixing reagent grade calcium ascorbate with
Test A - Threonic Acid (calcium salt) Test B - Xylonic Acid (calcium salt) Test C - Lyxonic Acid (calcium salt)
in the same weight proportions as the components are found in Example 7.
The tests of Example 2 are repeated using these test compounds and using pure calcium ascorbate as an additional control.
These tests confirm that the physiological activity of the mixed ascorbate - aldonic product is due to the aldonic component and that any one of these aldonic components causes the similarly improved absorption and retention of the Vitamin C component.
Claims
1. A composition comprising:
(a) a compound having Vitamin C activity; and
(b) at least one compound selection from the class consisting of the aldono lactones and edible salts of L-threonic, L-xylonic and L- lyxonic acids.
2. The method for improving the body absorption rate of a compound having Vitamin C activity comprising incorporating therein a minor effective amount of metabolite of said compound.
3. A method for establishing body Vitamin C levels including the step of orally administering to a subject a composition comprising:
(a) A compound having Vitamin C activity; and
(b) at least one compound selected from the class consisting of the aldono lactones and edible salts of L-threonic, L-xylonic and L- lyxonic acids.
4. A method for establishing Vitamin C levels in a subject comprising:
(a) converting L-ascorbic acid to a composition comprising: (i) a compound having Vitamin C activity, and
(ii) at least one compound selected from the class consisting of the aldono lactones and edible salts of L-threonic, L-xylonic and L- lyxonic acids;
and
(b) orally administering said composition to said subject.
Priority Applications (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US1989/001642 WO1990012571A1 (en) | 1989-04-07 | 1989-04-07 | Compositions and methods for administering vitamin c |
PCT/US1989/004046 WO1990003167A1 (en) | 1988-09-19 | 1989-09-15 | Compositions and methods for administering therapeutically active compounds |
AU43288/89A AU621672C (en) | 1988-09-19 | 1989-09-15 | Compositions and methods for administering therapeutically active compounds |
AT89910989T ATE160939T1 (en) | 1988-09-19 | 1989-09-15 | COMPOSITIONS AND METHODS OF ADMINISTRATION FOR REMEDIES |
KR1019900700824A KR940000006B1 (en) | 1988-09-19 | 1989-09-15 | Pharmaceutical active compounds compositions |
DE68928488T DE68928488T2 (en) | 1988-09-19 | 1989-09-15 | COMPOSITIONS AND METHODS OF ADMINISTRATION FOR MEDICINAL PRODUCTS |
SU4830452/14A RU2059410C1 (en) | 1988-09-19 | 1989-09-15 | Therapeutic composition |
EP89910989A EP0417209B1 (en) | 1988-09-19 | 1989-09-15 | Compositions and methods for administering therapeutically active compounds |
JP1510161A JP2973365B2 (en) | 1988-09-19 | 1989-09-15 | Compositions for administering therapeutically active compounds |
CA000611779A CA1341434C (en) | 1988-09-19 | 1989-09-18 | Compositions and methods for administering therapeutically active compounds |
NZ230700A NZ230700A (en) | 1988-09-19 | 1989-09-19 | Use of l-threonic, l-xylonic and l-lyxonic acids and derivatives for increasing therapeutic effectiveness of pharmaceutical compositions |
NO902132A NO178056C (en) | 1988-09-19 | 1990-05-14 | Method of preparing a pharmaceutical composition with improved absorption, tolerance and / or retention rate |
DK199001242A DK175783B1 (en) | 1988-09-19 | 1990-05-18 | Agents and methods for administering therapeutically active compounds |
NO19944971A NO311219B1 (en) | 1988-09-19 | 1994-12-21 | Process for the preparation of a composition with enhanced vitamin C activity |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US1989/001642 WO1990012571A1 (en) | 1989-04-07 | 1989-04-07 | Compositions and methods for administering vitamin c |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1990012571A1 true WO1990012571A1 (en) | 1990-11-01 |
Family
ID=22214951
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1989/001642 WO1990012571A1 (en) | 1988-09-19 | 1989-04-07 | Compositions and methods for administering vitamin c |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO1990012571A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1039571C (en) * | 1996-06-13 | 1998-08-26 | 北京巨能经贸发展有限责任公司 | Calcium L-threonate for food additives and preparing process and use thereof |
EP1038524A1 (en) * | 1997-08-29 | 2000-09-27 | Beijing Juneng Asia-Pacific Life Scientific Research Center | L-threonate ferrous, as well as pharmaceutical composition and use for improving and treating human anemia thereof |
EP1124550A1 (en) * | 1999-08-30 | 2001-08-22 | Oxycal Laboratories, Inc. | Methods and compositions for selective cancer chemotherapy |
EP0713650B2 (en) † | 1994-11-23 | 2003-01-08 | Societe Des Produits Nestle S.A. | Process and apparatus for producing aerated frozen products |
EP1286674A1 (en) * | 2000-09-01 | 2003-03-05 | Oxycal Laboratories, Inc. | Methods and compositions for potentiating cancer chemotherapeutic agents |
US6613374B1 (en) | 1995-11-14 | 2003-09-02 | Nestec S.A. | Frozen confectionery product and method of manufacture |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3459863A (en) * | 1966-10-14 | 1969-08-05 | Merck & Co Inc | Color-stable ascorbic acid tablet |
US3781423A (en) * | 1968-01-18 | 1973-12-25 | Takeda Chemical Industries Ltd | Method for preventing coloring of vitamin c |
-
1989
- 1989-04-07 WO PCT/US1989/001642 patent/WO1990012571A1/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3459863A (en) * | 1966-10-14 | 1969-08-05 | Merck & Co Inc | Color-stable ascorbic acid tablet |
US3781423A (en) * | 1968-01-18 | 1973-12-25 | Takeda Chemical Industries Ltd | Method for preventing coloring of vitamin c |
Non-Patent Citations (2)
Title |
---|
JOURNAL OF CHEMICAL TOXICITY, Volume 21, No. 4, published 1983, (Great Britain), THOMAS: "A Relationship Between Ascorbic Acid and Threonic Acid in Guinea-Pigs", see pages 449-452. * |
VITAMIN C: "Its Molecular Biology and Medical Potential", (LEWIN), published 1976, ACADEMIC PRESS, New York, New York, see pages 12-13. * |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0713650B2 (en) † | 1994-11-23 | 2003-01-08 | Societe Des Produits Nestle S.A. | Process and apparatus for producing aerated frozen products |
US6613374B1 (en) | 1995-11-14 | 2003-09-02 | Nestec S.A. | Frozen confectionery product and method of manufacture |
CN1039571C (en) * | 1996-06-13 | 1998-08-26 | 北京巨能经贸发展有限责任公司 | Calcium L-threonate for food additives and preparing process and use thereof |
EP1038524A1 (en) * | 1997-08-29 | 2000-09-27 | Beijing Juneng Asia-Pacific Life Scientific Research Center | L-threonate ferrous, as well as pharmaceutical composition and use for improving and treating human anemia thereof |
EP1038524A4 (en) * | 1997-08-29 | 2002-08-07 | Beijing Juneng Asia Pacific Li | L-threonate ferrous, as well as pharmaceutical composition and use for improving and treating human anemia thereof |
EP1124550A1 (en) * | 1999-08-30 | 2001-08-22 | Oxycal Laboratories, Inc. | Methods and compositions for selective cancer chemotherapy |
EP1124550A4 (en) * | 1999-08-30 | 2002-08-21 | Oxycal Lab Inc | Methods and compositions for selective cancer chemotherapy |
AU783283B2 (en) * | 1999-08-30 | 2005-10-13 | Ester C Company, The | Methods and compositions for selective cancer chemotherapy |
EP1286674A1 (en) * | 2000-09-01 | 2003-03-05 | Oxycal Laboratories, Inc. | Methods and compositions for potentiating cancer chemotherapeutic agents |
EP1286674A4 (en) * | 2000-09-01 | 2005-12-21 | Oxycal Lab Inc | Methods and compositions for potentiating cancer chemotherapeutic agents |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4822816A (en) | Compositions and methods for administering vitamin C | |
US4968716A (en) | Compositions and methods for administering therapeutically active compounds | |
US5070085A (en) | Compositions and methods for administering therapeutically active compounds | |
Fleming et al. | Selenium deficiency and fatal cardiomyopathy in a patient on home parenteral nutrition | |
Marie et al. | Effect of stable strontium on bone metabolism in rats | |
Van Dyck et al. | Bioavailability of silicon from food and food supplements | |
WO1996036585A1 (en) | A new process for the production of potassium hydroxy citric acid, and compositions containing the potassium hydroxy citric acid | |
Beutler | Iron enzymes in iron deficiency. VI. Aconitase activity and citrate metabolism | |
WO1990012571A1 (en) | Compositions and methods for administering vitamin c | |
US2777859A (en) | Warfarin-alkali metal derivatives and processes of preparing the same | |
Richards et al. | Studies on cyclamate sodium (sucaryl sodium), a new noncaloric sweetening agent | |
Fausa et al. | Intractable watery diarrhoea, hypokalaemia, and achlorhydria associated with non-pancreatic retroperitoneal neurogenous tumour containing vasoactive intestinal peptide (VIP) | |
JP2002121134A (en) | Use of lipoic acid for improving bioavailability of mineral salt | |
Pickett et al. | Evidence for dietary essentiality of lithium in the rat | |
FI97950C (en) | Method of making a vitamin product | |
US5677461A (en) | Method for producing chromium picolinate complex | |
US8957111B2 (en) | Strontium (M) ascorbate, compositions containing same, method for making same and method of using same | |
Mehlman et al. | Oxidative phosphorylation and respiration by rat liver mitochondria from aspirin-treated rats | |
KR940000006B1 (en) | Pharmaceutical active compounds compositions | |
AU621672C (en) | Compositions and methods for administering therapeutically active compounds | |
Hämäläinen et al. | Alterations in electrolyte and iron metabolism in the rat in relation to peroral administration of galactitol, mannitol and xylitol | |
Saikkonen | Cobalt as a producer of porphyrinuria and polycythemia | |
Dent et al. | Porphyrinuria in rats fed oxidized-casein: a preliminary communication | |
EP0634105B1 (en) | Calcium containing composition | |
JPS61172821A (en) | Manufacture of novel hemine complex compound for medicinal use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU DK FI JP KR NO SU |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE FR GB IT LU NL SE |